Original ArticlesColesevelam HCl and Ezetimibe Combination Therapy Provides Effective Lipid-Lowering in Difficult-to-Treat Patients with HypercholesterolemiaZema, Michael JAuthor Information Division of Cardiology, Department of Medicine, Brookhaven Memorial Hospital Medical Center, Patchogue, New York; and State University of New York, Stony Brook, New York. The publication of this study was supported by a grant from Sankyo Pharma Inc.; however, no financial support was provided by any pharmaceutical company or any other outside agency for the conducting of the study. Address for correspondence: Brookhaven Memorial Hospital Medical Center, 101 Hospital Road, Patchogue, NY 11772. E-mail: [email protected] American Journal of Therapeutics: July 2005 - Volume 12 - Issue 4 - p 306-310 doi: 10.1097/01.mjt.0000155109.69831.a3 Buy Metrics Abstract This study investigated the effects of colesevelam hydrochloride (WelChol; Sankyo Pharma, Parsippany, NJ) and ezetimibe (Zetia; Merck/Schering Plough Pharmaceuticals, North Wales, PA), alone and in combination, for the treatment of hypercholesterolemia in patients who were intolerant to, or refused, HMG-Co-A reductase inhibitor (statin) therapy. Combination therapy with colesevelam HCl/ezetimibe resulted in an additional reduction in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (HDL-C) levels of approximately 20% (P < 0.005) and 16% (P < 0.01), respectively, compared with monotherapy with either agent. Total cholesterol, LDL-C, and non-HDL-C levels were within National Cholesterol Education Program Adult Treatment Panel III target ranges at the end of the combination therapy regimen in 10 of 12 patients. In conclusion, colesevelam HCl/ezetimibe combination therapy appears to be an efficacious and well-tolerated alternative for patients with hypercholesterolemia. © 2005 Lippincott Williams & Wilkins, Inc.